PDGFRA and gastrointestinal stromal tumor: The positive response of IM use with a median treatment duration of 55 months [7] is quite evident in some patients with specific molecular subtypes (KIT/PDGFRA wild type and PDGFRA D842V mutant); indeed, the PDGFRA D842V mutation creates a missense mutation conferring resistance to IM with poor prognostic outcomes in GIST patients [8].